Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463359
Status:
UNKNOWN
Last Update Posted:
2007-04-20
First Post:
2007-04-19
Brief Title:
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
Sponsor:
University of Glasgow
Organization:
University of Glasgow
Study Overview
Official Title:
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication cautery followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone
Detailed Description:
Basal Cell Carcinomas BCC are the commonest form of skin cancer in the white population The face is where they most frequently occur and the nodular BCCs are the commonest type Curettage and cauteryelectrodessication CC has been an established way of management of nodular BCCs for years being a simple surgical procedure readily performed in outpatient clinics with good aesthetic results and high cure rates The purpose of this study is to determine recurrence rates of nodular BCCs on the face removed with CC followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with CC alone Imiquimod is an immune response modifier with anti-tumour effects already licensed for the treatment of superficial BCCs in the UK
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2007-001961-14 | None | None | None |